You are here

Articles

Leukemia Insights: Vol. 16, No. 1 Spring 2011

published: 27 April 2011

Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

published: 21 April 2011

Dasatinib vs imatinib -newly diagnosed CML cp

published: 25 March 2011

Nilotinib versus imatinib -newly diagnosed CML

published: 25 March 2011

TKI's in CML: Passing the Baton

published: 25 March 2011

Blocking rogue gene could stop the spread of most cancers

published: 25 January 2011

BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP

published: 16 January 2011

Seeking the causes of and solutions to imatinib resistance in CML

published: 16 January 2011

First-line dasatinib, nilotinib sustain their edge over imatinib

published: 16 January 2011

ASH 2010 - pick of abstracts

published: 1 December 2010

Oncologystat- CML The Changing Landscape: Interview with Prof. Apperley-Parts 1 and 2

published: 25 November 2010

ASH 2010 - Orlando

published: 9 November 2010

Nature News- Cellular 'alchemy' transforms skin into blood 7/11/2010

published: 9 November 2010

Advances in the Treatment and Management of Patients With CML: A Nurse's Perspective CE Patricia S. Ault, MSN, RN

published: 21 October 2010

Second-Generation BCR-ABL Kinase Inhibitors in CML

published: 21 October 2010

CHMP positive recommendation for use of Tasigna in Newly Diagnosed Ph+ CML

published: 25 September 2010

Changing the Culture of Clinical Trials: Reviving a Failing Effort

published: 22 September 2010

NEJM article: “Liberating the NHS” — Another Attempt to Implement Market Forces in English Health Care

published: 22 September 2010

New BCR/Abl Inhibitor from Ariad Pharmaceuticals

published: 21 September 2010

Blood Journal-Long-term prognostic significance of early molecular response to imatinib

published: 25 August 2010